InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants
November 13, 2025
NanoViricides, Inc. (NYSE American: NNVC), closed its previously announced $6 million registered direct offering of 3,571,429 shares of common stock at $1.68 per share with a single healthcare institutional investor, alongside a concurrent private placement of Series A and Series B warrants for an equal number of shares with exercise prices of $1.75 and $2.00, […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants
November 11, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral nanomedicines, today announced it has entered into a securities purchase agreement with a single healthcare institutional investor for the purchase of 3,571,429 shares of common stock (or equivalents) at $1.68 per share in a registered direct offering, for expected gross proceeds of approximately $6 […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC
November 10, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced that the Democratic Republic of Congo’s regulatory agency, ACOREP, has approved the start of a Phase II clinical trial evaluating NV-387 for the treatment of MPox caused by hMPXV infection. The trial will assess safety and effectiveness, pending final document submissions. “This is an important milestone in regulatory development […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting
November 5, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to prevent viral escape, announced that its Annual Shareholders Meeting will be held at 10 a.m. on Saturday, Nov. 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. To view the full press release, visit https://ibn.fm/7IcXQ ABOUT NANOVIRICIDES NanoViricides, Inc. […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at Spartan Capital Investor Conference 2025
November 3, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antiviral drugs designed to prevent viral escape, announced it will present today, Nov. 3, 2025, at 9:45 a.m. ET at the Spartan Capital Investor Conference in New York City. To view the full press release, visit https://ibn.fm/cnCIM About NanoViricides NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Potent Anti-Measles Results for NV-387 in Proactive Interview
October 29, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced that CEO Dr. Anil Diwan discussed major advances in the company’s antiviral research during a video interview with Proactive, available at https://youtu.be/m_3Yk4_832E. Dr. Diwan reported that NanoViricides’ lead candidate, NV-387, showed strong anti-Measles activity in both cell culture and humanized animal models, extending survival by 130% and protecting lung tissue in severe […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at PODD 2025 Conference in Boston
October 27, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to prevent viral escape, will present at the PODD 2025 Conference on Monday, Oct. 27, at 3 p.m. ET in Track 5A at the Westin Copley Hotel, Boston. President and Executive Chairman Anil R. Diwan, PhD, will provide updates on the company’s […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Strong Antiviral and Lung-Protective Activity of NV-387 Against Measles
October 23, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical lead drug candidate, NV-387, demonstrated potent antiviral effects against the Measles virus in both cell culture studies and a humanized animal model. NV-387 treatment extended survival in infected mice by 130%, from 7.4 to 17 days, while significantly protecting lung tissue from viral and immune-related damage. […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387
October 15, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced that Proactive Investors published an analyst research report detailing the Company’s dual-track clinical development strategy for NV-387, its broad-spectrum antiviral drug candidate targeting both MPox and respiratory viral infections, including influenza, coronaviruses, and RSV. The report notes NV-387’s nano-polymer micelle technology, which binds and neutralizes virus particles before they […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
September 10, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to resist viral escape, announced it will present at the Life Science Executive Partnering (LSX) World Congress 2025 in Boston on Wednesday, Sept. 17, at 12:30 p.m. To view the full press release, visit https://ibn.fm/uoB3n ABOUT NANOVIRICIDES NanoViricides, Inc. is a clinical-stage […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Treatment for Growing Measles Outbreaks
July 30, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antivirals using host-mimetic nanomedicine technology, announced its drug candidate NV-387 could address rising measles cases in the United States, Canada, the UK and European Union. NV-387 has shown effectiveness and safety in animal studies using humanized h-CD150+ knock-in mice and completed a Phase I clinical […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387’s Broad Antiviral Potential and Strategic Value for Pandemic Preparedness
July 23, 2025
NanoViricides, Inc. (NYSE American: NNVC) emphasized the broad-spectrum antiviral effectiveness of its nanomedicine candidate NV-387, citing promising data across viruses including MPox, Smallpox, Measles, Influenza, and Coronaviruses. The company plans to launch a Phase II trial for MPox, which could position NV-387 as the first approved treatment for the virus. With shared development costs across […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study
July 21, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals using host-mimetic nanomedicine, announced promising results for NV-387, its lead drug candidate, in treating Measles. In a lethal respiratory infection model using humanized mice, NV-387 increased survival by 130%—from 7.4 to 17 days—with no observed toxicity and dose-dependent efficacy. The drug mimics human cell […]
InvestorNewsBreaks – NanoViricides, Inc. (NYSE American: NNVC) Highlights MPox Drug Progress as WHO Extends Global Health Emergency
July 16, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued global MPox threat following the WHO’s extension of the Public Health Emergency of International Concern (PHEIC). The company emphasized the potential of NV-387, its broad-spectrum antiviral, which has completed Phase I trials with a strong safety profile […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Finalizes Adaptive Trial Design for MPox Drug NV-387
July 14, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clinical trial protocol for MPox Clade Ia and Ib, targeting about 80 patients in the Democratic Republic of Congo. The two-part Phase II trial will assess safety, dosing, and efficacy of NV-387 oral gummies—formulated to ease administration for patients […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
June 18, 2025
NanoViricides, Inc. (NYSE American: NNVC) asserts that its antiviral candidate NV-387 is uniquely positioned to address rising global threats from emerging COVID-19 variants like NB1.8.1 “Nimbus” and evolving strains of Bird Flu, including highly pathogenic genotypes identified in the U.S. and Cambodia. NV-387, which has completed Phase I trials without adverse events, is designed as […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
June 4, 2025
NanoViricides, Inc. (NYSE American: NNVC) has initiated an animal trial to evaluate its clinical-stage antiviral candidate NV-387 for Measles, targeting a rising global health threat amid vaccine failures and declining immunization rates. Using genetically modified mice expressing the human CD150/SLAM receptor required for viral entry, the study aims to confirm NV-387’s potential as the first […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
May 28, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced it will present at the BIO International Convention 2025 in Boston on Monday, June 16 at 2:30 p.m. ET. Dr. Anil R. Diwan, President and Executive Chairman, will provide updates on the company’s drug pipeline and licensing-ready platform technologies. The presentation will focus on NV-387, a broad-spectrum antiviral nearing […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
May 22, 2025
NanoViricides, Inc. (NYSE American: NNVC) President Dr. Anil Diwan applauded the FDA’s updated COVID-19 booster shot policy, which now limits widespread recommendations and focuses on high-risk groups such as seniors and those with co-morbidities. Diwan praised the shift to evidence-based guidance and emphasized how the new policy aligns with global standards. He added that broad […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
May 16, 2025
NanoViricides, Inc. (NYSE American: NNVC) filed its Q1 2025 report and announced progress on NV-387, its broad-spectrum antiviral drug candidate. The company has received clearance from the DRC’s National Ethics Committee to submit a Phase II trial application for MPox and is also initiating programs targeting measles and avian flu. NV-387 previously completed Phase I […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
May 14, 2025
NanoViricides, Inc. (NYSE American: NNVC) provided a strategic update on its antiviral pipeline, highlighting NV-387 as a potential breakthrough treatment for Measles and MPox amid rising global case counts and vaccine failures. The company has begun preparations for animal efficacy studies for Measles and will make NV-387 available under FDA’s Individual Patient Expanded Access. In […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC
May 8, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced approval from the Democratic Republic of Congo’s National Ethics Committee for Health for its planned Phase II clinical trial of NV-387, a broad-spectrum antiviral targeting Mpox (hMPXV). The company is finalizing its Clinical Trial Application for submission to the Ministry of Public Health. NV-387, a host-mimetic antiviral, has shown […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at D. Boral Capital Inaugural Global Conference
May 5, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antivirals using host-mimetic nanomedicine technology, will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. Anil R. Diwan, President and Executive Chairman, is scheduled to host one-on-one meetings with investors from 9 a.m. […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387
April 29, 2025
NanoViricides, Inc. (NYSE American: NNVC) provided an update on its Measles drug development program, highlighting the potential of its broad-spectrum antiviral candidate NV-387. With declining vaccination rates raising the risk of measles becoming endemic in the United States, the company emphasized the need for an effective antiviral treatment. NV-387, which has shown success against related […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
March 11, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, announced that its business remains unaffected by U.S. tariff policies and government spending cuts. The company reaffirmed its focus on antiviral treatments rather than vaccines, citing strong potential for its lead candidate, NV-387, in treating measles, MPox, influenza, and COVID-19. NanoViricides is preparing […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
March 4, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced that its broad-spectrum antiviral, NV-387, may be a potential treatment for measles amid the ongoing outbreak. The company emphasized the urgency of addressing the lack of an approved antiviral for measles, aligning with recent remarks by HHS Secretary Robert F. Kennedy Jr. in a Fox News opinion piece. NV-387 […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
February 19, 2025
NanoViricides, Inc. (NYSE American: NNVC) has filed its quarterly report for the period ending Dec. 31, 2024, with the SEC, reporting cash and cash equivalents of $3.96 million and net property and equipment assets of $7.17 million. The company raised $4 million through an At-the-Market offering but indicated it lacks sufficient funding to sustain operations […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
February 11, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced its broad-spectrum antiviral NV-387 as a potential solution for combating H5N1 bird flu, stating that the virus is unlikely to develop resistance to the drug. The company highlighted NV-387’s demonstrated efficacy against various viruses, including influenza, coronaviruses, RSV and poxviruses, in preclinical studies. CEO Anil R. Diwan criticized past […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Showcases NV-387’s Broad-Spectrum Antiviral Potential at MicroCap Conference
January 29, 2025
NanoViricides, Inc. (NYSE American: NNVC) presented its latest advancements at the MicroCap Conference 2025 in Atlantic City on Jan. 29, highlighting its lead drug candidate, NV-387. The company is preparing for Phase II clinical trials of NV-387 for MPOX treatment in Africa, where the virus remains a public health concern. Designed to target a host-side […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Partners with CRO to Advance NV-387 Antiviral Drug to Phase II Trials
January 27, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced it has engaged a Clinical Research Organization (“CRO”) to conduct a Phase II clinical trial for its broad-spectrum antiviral drug, NV-387. The host-mimetic drug, which mimics cellular attachment receptors to block viral infections, has demonstrated strong antiviral activity in preclinical models against orthopoxviruses, including MPox and Smallpox, and outperformed […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Broad-Spectrum Antiviral Innovations at Biotech Showcase 2025
January 13, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs designed to resist viral escape, announced it will present at the Biotech Showcase™ 2025 on Jan. 14 in San Francisco. Anil R. Diwan, PhD, the company’s president and executive chairman, will provide updates on NanoViricides’ pipeline, including NV-387, a Phase II-ready drug with potential […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as a Broad-Spectrum Antiviral Solution to Emerging Threats
January 8, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced significant progress on NV-387, a broad-spectrum antiviral demonstrating superior efficacy in animal models against rapidly mutating RNA viruses, including H5N1 bird flu, RSV, hMPV, and lethal coronaviruses. As viruses like H5N1 evolve to evade vaccines and existing drugs, NV-387’s mechanism, mimicking host cell features required for infection, minimizes resistance […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Touts NV-387 as Key Defense Against Potential Bird Flu Pandemic
December 23, 2024
NanoViricides, Inc. (NYSE American: NNVC) has highlighted its broad-spectrum antiviral drug candidate, NV-387, as a crucial tool to combat a potential H5N1 bird flu pandemic. According to Anil R. Diwan, Ph.D., President and Executive Chairman of the company, NV-387 targets essential host-side features that the rapidly evolving H5N1 virus relies on, making it less likely […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
November 15, 2024
NanoViricides, Inc. (NYSE American: NNVC), has filed its Quarterly Report for the period ending Sept. 30, 2024, detailing $3.87 million in cash and cash equivalents, $7.36 million in net property and equipment assets, and $1.63 million in current liabilities. The company utilized $2.6 million in operating activities during the quarter, including $1 million for R&D […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
November 4, 2024
NanoViricides (NYSE American: NNVC) will present a corporate update at the Spartan Capital Investors Conference today, Nov. 4, 2024, at 9:45 a.m. ET, detailing its lead antiviral drug candidate, NV-387, which is Phase 2-ready and targets a broad range of viral infections. Dr. Anil R. Diwan, the company’s President and Executive Chairman, highlighted NV-387’s successful […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
October 22, 2024
NanoViricides (NYSE American: NNVC) announced that its President and Executive Chairman, Dr. Anil R. Diwan, will present at the PODD Conference on Oct. 28, 2024, highlighting the company’s innovative nanomedicine platform and its antiviral drug candidate NV-387. Dr. Diwan will discuss the platform’s ability to revolutionize drug delivery by enhancing bioavailability and protecting drugs from […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
October 15, 2024
NanoViricides (NYSE American: NNVC), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, is in the spotlight in the most recent episode of the PODD podcast. The company announced that president and executive chair Anil R. Diwan, PhD, was interviewed during the Oct. 11 episode of the program, which was released on PharmaTalkRadio. During the interview, […]
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
October 8, 2024
NanoViricides (NYSE American: NNVC) is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. NanoViricides’ President and Executive Chairman Anil R. Diwan, Ph.D., is expected to present at the Global AMR Summit, the premier forum for anti-microbial resistance (“AMR”), to be held at the Kimpton Marlowe Hotel in Cambridge, MA, on October […]
InvestorNewsBreaks – Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) Schedules Annual General and Special Meeting to Vote on Proposed Spin-Out of Winston Properties
September 30, 2024
Foremost Clean Energy (NASDAQ: FMST) (CSE: FAT), an emerging North American uranium and lithium exploration company, today announced that its Annual General and Special Meeting of shareholders will be held on December 9, 2024, at 11 a.m. (Vancouver time). At the meeting, shareholders of record on November 6, 2024, will vote on, among other things, […]
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
September 30, 2024
NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, on September 27, 2024. The company reported cash and cash equivalents of $4.97 million, approximately $7.5 million in Net Property and Equipment (“P&E”) assets […]